

ASX RELEASE

27 August 2021

Annual General Meeting – CEO Presentation

Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) is pleased to release the Chief Executive Officer’s presentation to the Annual General Meeting which is to be held at 12.00 midday today.

The Annual General Meeting will be held via a Webinar. To register for participation in the Webinar please click on this link: <https://bit.ly/3jQEK08>

This ASX announcement authorised for release by the Board.

- End -

For Further Information

Dr. John Lambert
Chief Executive Officer
john@ampliatx.com
www.ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and fibrosis and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. In addition, the company is pursuing the potential of its FAK inhibitors in pulmonary fibrosis.

2021 Annual General Meeting CEO Presentation

27 August 2021

Amplia Therapeutics Limited



Disclaimer



The information contained in the presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Amplia Therapeutics Limited (“Amplia”) in any jurisdiction. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained in this document or opinions expressed in the course of this presentation. The information contained in this presentation is subject to change without notification.

This presentation contains forward-looking statements which can be identified by the use of words such as “may”, “should”, “will”, “expect”, “anticipate”, “believe”, “estimate”, “intend”, “scheduled” or “continue” or similar expressions. Any forward-looking statements contained in this presentation are subject to significant risks, uncertainties, assumptions, contingencies and other factors (many of which are outside the control of, and unknown to Amplia, and its officers, employees, agents or associates), which may cause the actual results or performance to be materially different from any future result so performed, expressed or implied by such forward-looking statements.

There can be no assurance or guarantee that actual outcomes will not differ materially from these statements. The data and results pertaining to clinical subjects used in this presentation are illustrative of medical conditions and outcomes associated with potential applications of Amplia’s acquired product pipeline. Actual results from clinical trials may vary from those shown.

Company Highlights



Clinical stage company developing small molecule drugs against Focal Adhesion Kinase (FAK) for two, significant disease areas:

- Cancer – combination therapy in hard-to-treat solid tumours
- Fibrosis – prevention and treatment

Phase 1 clinical trial of AMP945 completed


- Oral doses of AMP945 were safe and well tolerated, trial data strongly supports further development

Two Phase 2 clinical trials planned to start within 12 months

- Pancreatic cancer
- Pulmonary fibrosis



Focal Adhesion Kinase – one drug target, multiple opportunities



Focal Adhesion Kinase (FAK)

Indication

FIBROTIC DISEASES

SOLID CANCERS

Biology

- Collagen accumulation
- Collagen crosslinking
- Fibronectin production

- Cell migration and metastasis
- Collagen accumulation
- Local regulation of immune response

Opportunities

- Lung fibrosis
- Liver fibrosis
- Renal fibrosis

- Pancreatic cancer
- Ovarian cancer
- Breast cancer
- Liver cancer

Preclinical data supports dual indications




Lung Fibrosis

AMP945 reduces lung fibrosis in widely accepted disease model


control – healthy lung



bleomycin – fibrotic lung





bleomycin + AMP945



Pancreatic Cancer

AMP945 increases survival in aggressive mouse model of pancreatic cancer



Amplia's target indications



Idiopathic Pulmonary Fibrosis (IPF)

- Affects 130,000 in the US and ~3M people worldwide
- Devastating, progressive disease caused by the build up of fibrotic tissue in the lungs
- Only two drugs approved which slow progression but are unable to stop the disease
- With treatment, median survival time is 3-5 years


AMP945 was awarded Orphan Drug Designation by the US FDA for use in treating Idiopathic Lung Fibrosis in May 2020

Pancreatic Cancer

- 60,000 new diagnosis and 48,000 deaths from pancreatic cancer in the US each year
- Difficult-to-treat cancer that is often surrounded by a protective, fibrotic stromal layer
- Less than 20% patients eligible for surgery – chemo main treatment
- Few new therapies approved and most patients treated with cytotoxic chemotherapy drugs

AMP945 was awarded Orphan Drug Designation by the US FDA for use in treating Pancreatic Cancer in March 2020

Amplia's pipeline



The Year in Review



One year ago, Amplia was a preclinical-stage Company

Today, Amplia has completed its first clinical study is on the brink of two Phase 2 clinical studies


- Pancreatic cancer
- Pulmonary fibrosis

Main Achievements

- Commenced and completed Phase 1 trial of AMP945
- Raised \$3.8m to prepare for Phase 2 trials of AMP945
 - Backed by institutional investors Platinum, Blueflag and Acorn Capital
- Completed collaboration agreement with the Garvan Institute
- Reported that AMP945 increases survival in aggressive model of pancreatic cancer
- Planning for Phase 2 trial in pancreatic cancer is well advanced



Preclinical to Phase 2-ready in 12 months



Phase 1 Clinical Trial of AMP945



Summary of Outcomes

- Safe and well-tolerated at all doses tested
- No serious adverse events (SAEs) or withdrawals and no identified safety trends
 - Single ascending doses up to 125mg
 - Multiple ascending dose (100mg, once daily for 7 days)
- No detected food effect
- Once-a-day oral dose supported by pharmacokinetics
 - Predictable dose/exposure relationship
- Achieved blood levels of AMP945 expected to inhibit FAK

Solid platform for further development of AMP945 in cancer and fibrosis



AMP945 – 18-month development plan



Activity	CY2021		CY2022			
	Q3	Q4	Q1	Q2	Q3	Q4
HREC** filing		◆				
IND* filing			◆			
Phase 2 trial – pancreatic cancer			▶			
Phase 2 trial – pulmonary fibrosis					▶	

* Investigational New Drug Application – USA

** Human Research Ethics Committee - Australia

Upcoming targeted milestones



***Q3 2021**

- Phase 2 pancreatic cancer trial design complete

Q4 2021

- Phase 2 IND-enabling activities complete
- Ethics approval for Phase 2 pancreatic cancer trial

Q1 2022

- Initiate dosing in Phase 2 pancreatic cancer trial
- File IND for AMP945 in pancreatic cancer

Q2 2022

- Extended toxicology for AMP945 to support Phase 2 pulmonary fibrosis trial

* Calendar Quarters





ampliatx.com